Partner presentations reinforce ability of proprietary Azymetric™ platform to develop clinically validated therapeutic ...

Insulin efsitora alfa (investigational once-weekly basal insulin): In another ADA-sponsored symposium, Lilly will share results from the QWINT-1, QWINT-3 and QWINT-4 Phase 3 trials, which evaluated ...

Poster presentations across all programs, including data from HELIOS long-term extension trial of bitopertin in erythropoietic protoporphyria (EPP), additional durability data from Phase 1b study of ...

Paysign, Inc. (NASDAQ: PAYS), a leading provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services and integrated payment processing, today announced ...

Explore Allogene's innovative CAR-T therapies targeting cancer & autoimmune diseases. ASCO updates on ALLO-316 could validate ...

Terns Pharmaceuticals, Inc. ("Terns” or the "Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing ...

E4 Computer Engineering will be among the protagonists at ISC High Performance, Europe’s benchmark event for supercomputing, ...

A live webcast of Kiniksa's presentations will be accessible through the Investors & Media section of the company's website at . A replay of the events will also be available on Kiniksa's website ...

Newell Brands Inc. (NASDAQ: NWL) announced today that President and Chief Executive Officer, Chris Peterson, and Chief ...

Ongoing trade and macroeconomic uncertainties could create earnings headwinds for British American Tobacco and Philip Morris.

About PYRUKYND® (mitapivat) U.S. INDICATION PYRUKYND is a pyruvate kinase activator indicated for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency.

(NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Ltd., today announced it will share data across a range of hematologic malignancies at ...